Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE2601.15-0.1 (0 %)

PREV CLOSE ( ) 2601.25

OPEN PRICE ( ) 2551.50

BID PRICE (QTY) 2594.00 (2)

OFFER PRICE (QTY) 2599.20 (4)

VOLUME 2215

TODAY'S LOW / HIGH ( )2551.50 2625.40

52 WK LOW / HIGH ( )2022.05 3485.75

NSE2597.10-3.6 (-0.14 %)

PREV CLOSE( ) 2600.70

OPEN PRICE ( ) 2575.20

BID PRICE (QTY) 2595.50 (1)

OFFER PRICE (QTY) 2597.10 (2)

VOLUME 26129

TODAY'S LOW / HIGH( ) 2566.20 2627.50

52 WK LOW / HIGH ( )2327.3 3485

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta House,Charkop ,Kandivali (West),
Mumbai,
Maharashtra-400067

Phone 022-60609000 / 66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

02Sep Ajanta Pharma informs about analyst m
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

29Jul Ajanta Pharma informs about press rele
Ajanta Pharma has informed that it enclosed copies of financial results..

18Jul Ajanta Pharma informs about outcome of
Ajanta Pharma has informed that the 46th Annual General Meeting (AGM) of..

08Jul Ajanta Pharma informs about certificate
Ajanta Pharma has informed that it enclosed certificate under Regulation..

19Jun Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that the exchange has received Disclosure und..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	2549.7	9168.9
Gross Profit	3289.9	11800.6
Operating Profit	3700.3	13245.9
Net Sales	12085.6	43220.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14995.00 (2.67%)	M.Cap ( in Cr)18879.12
Astrazeneca Pharma I (BSE) 9201.05 (1.23%)	M.Cap ( in Cr)23002.63
Procter&Gamble Healt (BSE) 6520.00 (0.92%)	M.Cap ( in Cr)10822.80
Acutaas Chemicals (BSE) 1483.10 (4.05%)	M.Cap ( in Cr)12069.12
Glenmark Pharma (BSE) 2044.10 (2.69%)	M.Cap ( in Cr)57362.96

Shareholding Pattern

	PROMOTERS	66.26%
	MUTUAL FUNDS/UTI	14.72%
	NON-INSTITUTION	7.38%
	FI/BANKS/INSURANCE	2.01%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	4.92
Aditya Birla SL Pha...	3.96
NJ ELSS Tax Saver S...	3.47
PGIM India Healthca...	3.28
NJ Flexi Cap Fund-Reg(G)	3.10
Nippon India Pharma...	2.88
Kotak Healthcare Fu...	2.24

Risk Disclosures on Derivatives

Smart Quotes

AJANTA PHARMA LTD.